AstraZeneca Returns to CSPC in a $1.77B siRNA Kidney Pact as Takeda Bets Up to $600M on Insilico's AI Discovery Engine

Two China-linked platform licenses drove the week, both structured as discovery collaborations rather than clinical-asset deals. AstraZeneca returned to CSPC Pharmaceutical Group - its most active Chinese RNA partner - in a collaboration and license announced July 3 to develop small interfering RNA (siRNA) candidates against two undisclosed chronic kidney-disease pathways. AstraZeneca pays $30M upfront, with CSPC eligible for up to $540M in development and regulatory milestones and up to $1.2B in commercial-sales milestones (up to $1.77B total) plus royalties. AstraZeneca holds options to take global or ex-China rights depending on the program, while CSPC retains China rights to one preclinical candidate; the scientific emphasis is extrahepatic (renal) siRNA delivery combined with AI-driven molecular design. It is the latest in a run of AZ-CSPC RNA pacts that previously spanned obesity and cardiovascular disease.

A day earlier, on July 2, Takeda signed an AI drug-discovery collaboration with Hong Kong-based Insilico Medicine worth up to about $600M to Insilico - roughly $60M in project-initiation fees and near-term payments plus later preclinical, clinical, commercial and sales milestones and tiered royalties. Insilico's generative-AI Pharma.AI platform leads early discovery against agreed therapeutic priorities, and Takeda advances selected candidates through development and commercialization with worldwide rights. No major acquisition (control transaction) was announced in-window; the late-June M&A cluster (AbbVie-Apogee, Merck KGaA-Bio-Techne, Zymeworks-Theravance, Ipsen-Kartos) all fell just before this window. As always, BD professionals should anchor to near-term cash and de-risking: both in-window licenses again paired modest upfronts with billion-dollar-plus milestone tails on discovery-stage science.

June 30, 2026 - FDA Approves Orca Bio's Tregzi (Orca-T), the First Precision-Engineered Cell Therapy for Allogeneic Transplant

The FDA approved TREGZI (allogeneic regulatory T-cell immunotherapy with HSPC and T cells-vldq; clinically Orca-T), a precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation under a myeloablative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host-disease (GVHD)-free survival in adults with hematological malignancies. In the pivotal Precision-T study, 78% of Tregzi patients were alive and free of moderate-to-severe chronic GVHD at one year versus 38.4% with conventional allogeneic transplant, and severe chronic GVHD occurred in 12.6% versus 44%. It is the first and only precision-engineered cell therapy approved for allogeneic transplant.

BD Implication: A first-in-class engineered-Treg transplant product validates precision cell-engineering as a distinct, approvable modality and raises the bar for allo-transplant supportive care - a concrete Western differentiation benchmark for China-origin cell-therapy developers weighing US filings.

July 1, 2026 - FDA Expands Casgevy (exa-cel) to Children Aged 2 and Older with Sickle Cell Disease

The FDA granted a supplemental approval for Casgevy (exagamglogene autotemcel; Vertex Pharmaceuticals and CRISPR Therapeutics) for patients aged 2 and older with sickle cell disease with recurrent vaso-occlusive crises or with transfusion-dependent beta-thalassemia. Casgevy was previously approved for patients aged 12 and older; the expansion sets the lowest age threshold yet for a CRISPR-edited cell therapy in the United States.

BD Implication: Extending an ex vivo CRISPR therapy into younger pediatric sickle cell disease enlarges the addressable population for genetic medicines and reinforces the buyer and investor appetite that is pulling China-origin gene-editing programs, including in vivo base editors, into Western licensing conversations.

July 7, 2026 - FDA Decision Due on Vera Therapeutics Atacicept in IgA Nephropathy

Vera Therapeutics faces a July 7, 2026 FDA decision on its Biologics License Application, submitted under the Accelerated Approval pathway, for atacicept in adults with IgA nephropathy (IgAN). Atacicept is a recombinant fusion protein that inhibits B-cell activation by binding BAFF and APRIL, delivered as a once-weekly subcutaneous autoinjector. The pivotal ORIGIN Phase 3 trial met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria at week 36 in a prespecified interim analysis, with a safety profile comparable to placebo. (Presented as a pending decision; the outcome is not asserted here.)

BD Implication: A differentiated dual-cytokine (BAFF/APRIL) mechanism in an increasingly crowded IgAN field underscores that mechanism and route/dosing convenience drive positioning in autoimmune renal disease - directly relevant to the ANCA-associated vasculitis and anemia-of-CKD buyer mandates on the Opportunity Board.

Calendar and validation notes: Survodutide dual Phase 3 obesity and metabolic-liver-disease data was tied to ADA 2026 in mid-June and omitted as out-of-window. A Merck/Verona Pharma transaction surfaced under a July 8 date and a probable year mislabel and was omitted. AbbVie-Apogee, GSK-Nuvalent, and Merck KGaA-Bio-Techne M&A are all dated before June 30 and are excluded from the in-window M&A table.